Report : North America Skin Cancer Diagnostics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Melanoma and Non-Melanoma) and Screening Type (Blood Tests, Dermatoscopy, Imaging Tests, Lymph Node Biopsy, and Skin Biopsy)
Non-Melanoma Segment has the Largest Share of Type in the North America Skin Care Diagnostics Market during 2021–2028
According to our latest study on “North America Skin Care Diagnostics Market Forecast to 2028 – COVID-19 Impact and Analysis – by Type, and Screening Type,” the market is projected to reach US$ 2,354.2 million by 2028 from US$ 1,423.0 million in 2021; it is expected to grow at a CAGR of 7.5% from 2021 to 2028. The report highlights trends prevailing in the market, and the drivers and restraints pertaining to the market growth. The growth of this market is estimated to grow owing to key driving factors such as the increasing incidence of skin cancer and launch of new products. Whereas barriers to early skin cancer diagnostics in low and middle-income countries is the major factor restraining the growth of the market.
Based on type, the skin care diagnostics market is segmented into melanoma and non-melanoma. In 2021, the non-melanoma segment accounted for the largest market share in the North America skin cancer diagnostics market by type owing to rising awareness with respect to non-melanoma skin cancer. Non-melanoma skin cancers are more frequent than melanoma skin cancer.
SkylineDx BV; AMLo Biosciences Limited; DermLite LLC; bioMerieux SA; Veriskin Inc.; Castle Biosciences, Inc.; DermTech Inc.; F. Hoffmann-La Roche Ltd., and Michelson Diagnostics Ltd. are among the leading companies in the North America skin care diagnostics market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market.
The market for skin care diagnostics market is segmented into type and screening type. Based on type, the North America skin care diagnostics market is segmented into melanoma and non-melanoma. Based on screening type, the skin care diagnostics market is segmented into skin biopsy, dermatoscopy, lymph node biopsy, imaging tests, and blood tests. Geographically, the skin care diagnostics market is segmented into North America (US, Canada, Mexico).
Contact Person: Sameer Joshi
Email Id: firstname.lastname@example.org